Market Cap 271.88M
Revenue (ttm) 0.00
Net Income (ttm) -168.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 367,200
Avg Vol 411,460
Day's Range N/A - N/A
Shares Out 78.13M
Stochastic %K 86%
Beta 0.08
Analysts Sell
Price Target $6.00

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 284 8891
Address:
225 Franklin Street, Suite 2100, Boston, United States
JohnTrack
JohnTrack Jan. 8 at 3:48 PM
$AVIR keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 8 at 12:38 PM
$AVIR 2026 priorities https://www.rapidticker.com/news/avir-atea-pharmaceuticals-to-highlight-2026-56ad69
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 3:50 PM
$AVIR RSI: 70.72, MACD: 0.1026 Vol: 0.19, MA20: 3.23, MA50: 3.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DiaphragmD
DiaphragmD Dec. 27 at 5:14 AM
$AVIR Trading dynamics suggest reliability now matters more than momentum bursts. Resource allocation choices will signal strategic maturity. Execution consistency is the fastest path to confidence rebuilding. Compounding requires operational consistency.
0 · Reply
FATSTAX
FATSTAX Dec. 24 at 7:09 PM
0 · Reply
kubota2323
kubota2323 Dec. 24 at 3:31 PM
$KYTX adding $AVIR now . Very Bullish on both
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 24 at 5:07 AM
$AVIR Atea Pharmaceuticals Inc (NASDAQ:AVIR) has completed enrollment in a major Phase 3 hepatitis C trial, setting the stage for pivotal mid-2026 data that could reshape the antiviral treatment landscape. https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/
0 · Reply
Stmkr
Stmkr Dec. 23 at 11:34 AM
$AVIR https://seekingalpha.com/article/4855325-atea-pharmaceuticals-potential-best-in-class-hcv-cure-with-pivotal-readouts-in-2026
0 · Reply
prismmarketview
prismmarketview Dec. 22 at 2:54 PM
Atea Pharmaceuticals (NASDAQ: $AVIR) has finished enrolling 600 patients in its North American Phase 3 C‑BEYOND trial testing the all‑oral combo of bemnifosbuvir plus ruzasvir for chronic hepatitis C, with top‑line sustained virologic response (SVR12) data expected in the second half of 2026. https://prismmarketview.com/atea-pharmaceuticals-completes-enrollment-in-north-american-phase-3-hepatitis-c-trial/
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 2:39 PM
$AVIR Completes Patient Enrollment in North American Phase 3 Trial https://www.rapidticker.com/news/avir-atea-pharmaceuticals-completes-patient-enrollment-fc317
0 · Reply
Latest News on AVIR
JohnTrack
JohnTrack Jan. 8 at 3:48 PM
$AVIR keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 8 at 12:38 PM
$AVIR 2026 priorities https://www.rapidticker.com/news/avir-atea-pharmaceuticals-to-highlight-2026-56ad69
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 3:50 PM
$AVIR RSI: 70.72, MACD: 0.1026 Vol: 0.19, MA20: 3.23, MA50: 3.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DiaphragmD
DiaphragmD Dec. 27 at 5:14 AM
$AVIR Trading dynamics suggest reliability now matters more than momentum bursts. Resource allocation choices will signal strategic maturity. Execution consistency is the fastest path to confidence rebuilding. Compounding requires operational consistency.
0 · Reply
FATSTAX
FATSTAX Dec. 24 at 7:09 PM
0 · Reply
kubota2323
kubota2323 Dec. 24 at 3:31 PM
$KYTX adding $AVIR now . Very Bullish on both
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 24 at 5:07 AM
$AVIR Atea Pharmaceuticals Inc (NASDAQ:AVIR) has completed enrollment in a major Phase 3 hepatitis C trial, setting the stage for pivotal mid-2026 data that could reshape the antiviral treatment landscape. https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/
0 · Reply
Stmkr
Stmkr Dec. 23 at 11:34 AM
$AVIR https://seekingalpha.com/article/4855325-atea-pharmaceuticals-potential-best-in-class-hcv-cure-with-pivotal-readouts-in-2026
0 · Reply
prismmarketview
prismmarketview Dec. 22 at 2:54 PM
Atea Pharmaceuticals (NASDAQ: $AVIR) has finished enrolling 600 patients in its North American Phase 3 C‑BEYOND trial testing the all‑oral combo of bemnifosbuvir plus ruzasvir for chronic hepatitis C, with top‑line sustained virologic response (SVR12) data expected in the second half of 2026. https://prismmarketview.com/atea-pharmaceuticals-completes-enrollment-in-north-american-phase-3-hepatitis-c-trial/
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 2:39 PM
$AVIR Completes Patient Enrollment in North American Phase 3 Trial https://www.rapidticker.com/news/avir-atea-pharmaceuticals-completes-patient-enrollment-fc317
0 · Reply
G101SPM
G101SPM Dec. 22 at 12:10 PM
$AVIR $3.23 bid. DAC $3.21 (3.21.25). EXIT $7.50 BRIEF: Co announces completion of enrollment of more than 880 treatment-naïve patients in the C-BEYOND Phase 3 trial evaluating the fixed-dose combination (FDC) regimen of bemnifosbuvir and ruzasvir compared to the FDC regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). C-BEYOND is being conducted at approximately 120 clinical trial sites in the US and Canada. Phase 3 topline results are expected mid-year 2026. In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical trial sites in up to 17 countries outside of North America. Completion of enrollment in C-FORWARD is expected mid-year 2026, with Phase 3 topline results anticipated year-end 2026. In both studies, the FDC regimen of bemnifosbuvir and ruzasvir is administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the comparator FDC regimen of sofosbuvir and velpatasvir is administered orally once-daily for 12 weeks.
0 · Reply
Stmkr
Stmkr Dec. 22 at 10:20 AM
$AVIR I feel this one is seriously undervalued. What am I missing?
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 18 at 1:47 AM
$AVIR Share Price: $3.18 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $0.15 – $0.19 Target Zone: $0.26 – $0.32 Potential Upside: 61% ROI Time to Expiration: 211 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Zanetrades
Zanetrades Dec. 16 at 8:44 PM
0 · Reply
FATSTAX
FATSTAX Dec. 6 at 1:28 PM
$SPY $AVIR Daily & Hourly Pros = white candles 200 ema = aqua line Pros powering highs (November) flanked by pros dip buying (April & November) is a 52-week high breakout threat over the $3.18 11/13 high.
1 · Reply
npan
npan Dec. 5 at 7:23 PM
$AVIR fidelity (FMR) just reported in its 13g filing that it bought an extra 3plus million shares in AVIR meaning it now owns 11.6 percent of the company
1 · Reply
Cutlass
Cutlass Dec. 4 at 9:12 PM
0 · Reply
Cutlass
Cutlass Nov. 18 at 7:32 PM
$AVIR Sitting on a bundle of cash - 330M 💰
0 · Reply
Ah9020
Ah9020 Nov. 18 at 11:00 AM
$AVIR large block buys keep happening.
0 · Reply
PaulLaurent
PaulLaurent Nov. 16 at 8:12 PM
🧭 Weekly Swing Recap $IFRX – +25% from the entry zone. Steady push; trims into strength worked. $TNYA – +35% from the entry zone. Clean trend; partials on pushes paid. $GALT – +17% from the entry zone. Approach to first target; protect gains. $STRO – +24% from the entry zone. Higher-lows held; respect VWAP. $AVIR – ~+10% at peak, but catalyst reversal hit Stop-Loss if profits weren’t taken. GPRO – Near breakeven — small profit only, limited follow-through.
1 · Reply
Cutlass
Cutlass Nov. 13 at 3:02 PM
$AVIR 2.90 filled
0 · Reply
Cutlass
Cutlass Nov. 12 at 9:09 PM
$AVIR Long a 2026 Play 🍒
0 · Reply